RT Journal Article
SR Electronic
T1 A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 124263
DO 10.1101/124263
A1 Lia Gore
A1 Timothy J. Triche, Jr.
A1 Jason E. Farrar
A1 Daniel Wai
A1 Christophe Legendre
A1 Gerald C Gooden
A1 Winnie S. Liang
A1 John Carpten
A1 David Lee
A1 Frank Alvaro
A1 Margaret E. Macy
A1 Carola Arndt
A1 Philip Barnette
A1 Todd Cooper
A1 Laura Martin
A1 Aru Narendran
A1 Jessica Pollard
A1 Soheil Meshinchi
A1 Jessica Boklan
A1 Robert J Arceci
A1 Bodour Salhia
YR 2017
UL http://biorxiv.org/content/early/2017/06/14/124263.abstract
AB Background Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases, which has been studied extensively and is approved for myelodysplastic syndrome in adults but with less focus in children. Accordingly, we conducted a phase 1 multicenter, randomized, open-label study to evaluate decitabine pre-treatment before standard induction therapy in children with newly diagnosed AML to assess safety and tolerability and explore a number of biologic endpoints.Results Twenty-four patients were fully assessable for all study objectives per protocol (10 in Arm A, 14 in Arm B). All patients experienced neutropenia and thrombocytopenia. The most common grade 3 and 4 non-hematologic adverse events observed were gastrointestinal toxicities and hypophosphatemia. Plasma decitabine PK were similar to previously reported adult data. Overall CR/CRi was similar for the two arms. MRD negativity at end-induction was 85% in Arm A versus 67% in Arm B patients. DNA methylation measured in peripheral blood over the course of treatment tracked with blast clearance and matched marrow aspirates at day 0 and day 21. Unlike end-point marrow analyses, promoter methylation in blood identified an apparent reversal of response in the lone treatment failure, one week prior to the patient’s marrow aspirate confirming non-response. Decitabine-induced effects of end-induction marrows in Arm A were reflected by changes in DNA methylation and gene expression comparison with matched paired marrow diagnostic aspirates.Conclusions This first-in-pediatrics trial demonstrates that decitabine prior to standard combination chemotherapy is feasible and well tolerated in children with newly diagnosed AML. Pre-treatment with decitabine may represent a newer therapeutic option for pediatric AML, especially as it appears to induce important epigenetic alterations. The novel biological correlates studied in this trial offer a clinically relevant window into disease progression and remission. Additional studies are needed to definitively assess whether decitabine can enhance durability responses in children with AML. This trial was registered at www.clinicaltrials.gov as NCT01177540.